Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopyrrolate - Sunovion Respiratory Development/PARI Pharma

Next Previous
Drug Profile

Glycopyrrolate - Sunovion Respiratory Development/PARI Pharma

Alternative Names: EP-101; Glycopyrrolate bromide; Lonhala Magnair; SUN-101; SUN-101/eFlow®

Latest Information Update: 12 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elevation Pharmaceuticals
  • Developer PARI Pharma GmbH; Sunovion Respiratory Development
  • Class Antiasthmatics; Antispasmodics; Antiulcers; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Discontinued Asthma

Most Recent Events

  • 31 Dec 2023 Withdrawn for Chronic obstructive pulmonary disease in USA (Inhalation), prior to December 2023
  • 08 Sep 2021 Discontinued - Phase-II for Asthma in Germany (Inhalation) (Sunovion website, September 2021)
  • 17 May 2019 Efficacy and safety data from a phase III GOLDEN-3 and GOLDEN-4 trials in Chronic obstructive pulmonary disease presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top